User profiles for "author:D Cunningham"
David CunninghamThe Royal Marsden NHS Foundation Trust Verified email at rmh.nhs.uk Cited by 137346 |
The role of probiotics in aquaculture
…, I De Blas, I Ruiz-Zarzuela, D Cunningham… - Veterinary …, 2006 - Elsevier
The increase of productivity in aquaculture has been accompanied by ecological impacts
including emergence of a large variety of pathogens and bacterial resistance. These impacts …
including emergence of a large variety of pathogens and bacterial resistance. These impacts …
Oesophageal cancer
J Lagergren, E Smyth, D Cunningham, P Lagergren - The Lancet, 2017 - thelancet.com
Oesophageal cancer is a clinically challenging disease that requires a multidisciplinary
approach. Extensive treatment might be associated with a considerable decline in health …
approach. Extensive treatment might be associated with a considerable decline in health …
Oesophageal cancer
…, MA Shah, P Lagergren, D Cunningham - Nature reviews Disease …, 2017 - nature.com
Oesophageal cancer is the sixth most common cause of cancer-related death worldwide
and is therefore a major global health challenge. The two major subtypes of oesophageal …
and is therefore a major global health challenge. The two major subtypes of oesophageal …
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
JY Douillard, D Cunningham, AD Roth, M Navarro… - The Lancet, 2000 - thelancet.com
Background Irinotecan is active against colorectal cancer in patients whose disease is
refractory to fluorouracil. We investigated the efficacy of these two agents combined for first …
refractory to fluorouracil. We investigated the efficacy of these two agents combined for first …
[HTML][HTML] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham, Y Humblet, S Siena… - New England journal …, 2004 - Mass Medical Soc
Background The epidermal growth factor receptor (EGFR), which participates in signaling
pathways that are deregulated in cancer cells, commonly appears on colorectal-cancer …
pathways that are deregulated in cancer cells, commonly appears on colorectal-cancer …
[HTML][HTML] Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
D Cunningham, WH Allum, SP Stenning… - … England Journal of …, 2006 - Mass Medical Soc
Background A regimen of epirubicin, cisplatin, and infused fluorouracil (ECF) improves
survival among patients with incurable locally advanced or metastatic gastric …
survival among patients with incurable locally advanced or metastatic gastric …
[HTML][HTML] Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer
…, H Wasan, DH Palmer, D Cunningham… - … England Journal of …, 2010 - Mass Medical Soc
Background There is no established standard chemotherapy for patients with locally
advanced or metastatic biliary tract cancer. We initially conducted a randomized, phase 2 …
advanced or metastatic biliary tract cancer. We initially conducted a randomized, phase 2 …
[HTML][HTML] A prognostic score for advanced Hodgkin's disease
…, P Carde, D Crowther, D Cunningham… - … England Journal of …, 1998 - Mass Medical Soc
Background Two thirds of patients with advanced Hodgkin's disease are cured with current
approaches to treatment. Prediction of the outcome is important to avoid overtreating some …
approaches to treatment. Prediction of the outcome is important to avoid overtreating some …
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
…, M Verheij, W Allum, D Cunningham… - Annals of …, 2016 - annalsofoncology.org
Almost one million (951 600) new cases of gastric cancer were diagnosed globally in 2012,
resulting in∼ 723 100 deaths [1]. Of these∼ 140 000 cases and∼ 107 000 deaths occurred …
resulting in∼ 723 100 deaths [1]. Of these∼ 140 000 cases and∼ 107 000 deaths occurred …
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma …
…, N Sugimoto, O Lipatov, TY Kim, D Cunningham… - The lancet …, 2014 - thelancet.com
Background VEGFR-2 has a role in gastric cancer pathogenesis and progression. We
assessed whether ramucirumab, a monoclonal antibody VEGFR-2 antagonist, in …
assessed whether ramucirumab, a monoclonal antibody VEGFR-2 antagonist, in …